Glythera PermaLink™



Glythera’s PermaLink™ technology is a controlled, stable conjugation platform composed of a portfolio of linker designs. PermaLink™ can be employed for the selective and stable functionalization and conjugation of various cargos to proteins and peptides. 
Due to its increased stability and selectivity, PermaLink™ offers significant benefits in the development of next generation biologics: 
Antibody Drug Conjugates 
(ADCs) are highly potent biologics composed of a tumour specific antibody linked via a linker to a cytotoxic drug. One of the crucial requirements for improving the therapeutic window of ADCs is specific and stable attachment of a potent cytotoxic agent to the antibody via the linker. Benefits of using PermaLink™: 
  • Highly specific for the sulfhydryl groups of cysteine residues which are a primary site for cytotoxic drug attachment in many ADCs currently in clinical development 
  • Enhanced stability provided by a stable thioether bond which is resistant to biological and chemical degradation 
  • Compatible with a diverse range of cytotoxic payloads due to the ability to be tailored to generate both “non-cleavable” and “cleavable” linkers for efficient release of active drug following antigen-mediated internalization
  • Features

  • Comparative model system 
  • Controlled Drug to Antibody Ratio (DAR) 
  • Improved linker stability compared to maleimide based technologies 
  • Comparable in vitro activity 
  • Low immunogenic potential
  • Photos

    Manuals and Resources

    Note: We appreciate the support of individuals and companies making their documents and resources available to our community. If you find a document or resource that does not belong please let us know by emailing

    Picture of Glythera PermaLink™
    Glythera relocated to Newcastle-upon-Tyne in 2012, following investment from IP Group and the Finance for Business North East Technology Fund which underpinned...

    More about Glythera

    Questions and Answers

    Recent Question Activity

    Be the first to Ask a Question


    Member Reviews

    There are no threads in Glythera PermaLink™ Reviews at this time.
    Add a Review

    Glythera PermaLink™ Articles

    Helpful Resources, Articles, and Information

    Glythera Limited (Glythera), the next generation antibody drug conjugate (ADC) development company, and Cancer Research UK* today announced an...

    See All Related Articles